SCHEMBL144592

SCHEMBL144592

CCOC(=O)c1cc(=O)c2c(OCC(F)COc3cccc4oc(C(=O)OCC)cc(=O)c34)cccc2o1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 2/20 0.58
LMNA P02545 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
KMT2A Q03164 3/20 0.56
MEN1 O00255 2/20 0.56
HIF1A Q16665 1/20 0.56
ADRB2 P07550 4/20 0.48
NMT2 O60551 3/20 0.48
ADRB1 P08588 3/20 0.48
ADRB3 P13945 3/20 0.48
NMT1 P30419 3/20 0.48
MAPK1 P28482 1/20 0.48
AKR1B1 P15121 1/20 0.48
HPGD P15428 2/20 0.48
KDM4E B2RXH2 1/20 0.48
USP2 O75604 1/20 0.48
ALDH1A1 P00352 1/20 0.48
ATM Q13315 1/20 0.48
HSD17B10 Q99714 1/20 0.48
MAOB P27338 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25669938 0.96 GPR35 (0.54) GPR35LMNATDP1KMT2AMEN1
SCHEMBL115418 0.94 GPR35 (0.52) GPR35LMNATDP1KMT2AMEN1
SCHEMBL115378 0.94 GPR35 (0.52) GPR35LMNATDP1KMT2AMEN1
SCHEMBL116735 0.90 GPR35 (0.66) GPR35LMNATDP1KMT2AMEN1
SCHEMBL143979 0.90 GPR35 (0.72) GPR35LMNATDP1KMT2AMEN1
SCHEMBL179041 0.89 GPR35 (0.47) GPR35LMNATDP1KMT2AMEN1
SCHEMBL21556363 0.88 GPR35 (0.55) GPR35LMNATDP1KMT2AMEN1
SCHEMBL25472684 0.86 GPR35 (0.62) GPR35LMNATDP1KMT2AMEN1
SCHEMBL26645927 0.86 NMT2 (0.54) GPR35LMNATDP1KMT2AMEN1
SCHEMBL26848987 0.86 GPR35 (0.55) GPR35LMNATDP1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067635-A1 CROMOLYN DERIVATIVES AND USES THEREOF THE GENERAL HOSPITAL CORPORATION 2024-02-29 US disclosed
US-20240058480-A1 CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT THE GENERAL HOSPITAL CORPORATION 2024-02-22 US disclosed
US-11801316-B2 Cromolyn derivatives and related methods of imaging and treatment THE GENERAL HOSPITAL CORPORATION (US) 2023-10-31 US disclosed
US-11801316-B2 Cromolyn derivatives and related methods of imaging and treatment THE GENERAL HOSPITAL CORPORATION (US) 2023-10-31 US disclosed
EP-3506894-B1 MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES MASSACHUSETTS GEN HOSPITAL (US) 2023-08-23 EP disclosed
US-20230226017-A1 METHODS OF TREATING A CORONAVIRUS INFECTION MASSACHUSETTS GEN HOSPITAL (US) 2023-07-20 US disclosed
US-11679095-B2 Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases THE GENERAL HOSPITAL CORPORATION (US) 2023-06-20 US disclosed
US-11666669-B2 Cromolyn derivatives and related methods of imaging and treatment THE GENERAL HOSPITAL CORPORATION (US) 2023-06-06 US disclosed
US-11666669-B2 Cromolyn derivatives and related methods of imaging and treatment THE GENERAL HOSPITAL CORPORATION (US) 2023-06-06 US disclosed
US-20230149345-A1 METHODS OF TREATMENT OF CORONAVIRUS-INDUCED INFLAMMATION CONDITIONS THE GENERAL HOSPITAL CORPORATION 2023-05-18 US disclosed
US-20160263257-A1 CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT THE GENERAL HOSPITAL CORPORATION 2016-09-15 US disclosed
US-20160263257-A1 CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT THE GENERAL HOSPITAL CORPORATION 2016-09-15 US disclosed
EP-3060205-A1 CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT The General Hospital Corporation DBA Massachusetts (US) 2016-08-31 EP disclosed
WO-2015061397-A1 CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT THE GENERAL HOSTPITAL CORPORATION (US) 2015-04-30 WO disclosed
US-20140140927-A1 CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT THE GENERAL HOSPITAL CORPORATION (US) 2014-05-22 US disclosed
US-20140140927-A1 CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT THE GENERAL HOSPITAL CORPORATION (US) 2014-05-22 US disclosed
US-8617517-B2 Cromolyn derivatives and related methods of imaging and treatment THE GENERAL HOSPITAL CORPORATION (US) 2013-12-31 US disclosed
US-20120058049-A1 CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT THE GENERAL HOSPITAL CORPORATION 2012-03-08 US disclosed
EP-2391618-A2 CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT The General Hospital Corporation (US) 2011-12-07 EP disclosed
WO-2010088455-A2 CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT THE GENERAL HOSPITAL CORPORATION (US) 2010-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11801316-B2 Cromolyn derivatives and related methods of imaging and treatment PSEN1, PSEN2, CROCC GPR35 339/4885LMNA 62/4885TDP1 2301/4885
US-20240067635-A1 CROMOLYN DERIVATIVES AND USES THEREOF PRNP, HTT, CLN6 GPR35 1991/4885LMNA 111/4885TDP1 978/4885
US-20240058480-A1 CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT PSEN1, PSEN2, CROCC GPR35 332/4885LMNA 45/4885TDP1 2266/4885
US-11679095-B2 Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases CD68, PRNP, HTT GPR35 1528/4885LMNA 755/4885TDP1 3376/4885
US-20230149345-A1 METHODS OF TREATMENT OF CORONAVIRUS-INDUCED INFLAMMATION CONDITIONS C3AR1, IL5, C5 GPR35 359/4885LMNA 3678/4885TDP1 4796/4885
US-20230226017-A1 METHODS OF TREATING A CORONAVIRUS INFECTION CPA3, CMA1, ACE2 GPR35 1712/4885LMNA 2521/4885TDP1 3569/4885
US-20140140927-A1 CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT PSEN1, PSEN2, CROCC GPR35 332/4885LMNA 45/4885TDP1 2266/4885
US-20160263257-A1 CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT PSEN1, CROCC, PSEN2 GPR35 362/4885LMNA 32/4885TDP1 2625/4885
US-20120058049-A1 CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT CLN6, CA6, GALNT6 GPR35 699/4885LMNA 186/4885TDP1 1467/4885
US-11666669-B2 Cromolyn derivatives and related methods of imaging and treatment PSEN1, PSEN2, CROCC GPR35 332/4885LMNA 45/4885TDP1 2266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.